United Kingdom Prospective Diabetes Study (UKPDS) Legacy Study

Chief investigator:Rury Holman

Co-investigators:William Whiteley
Alastair Gray
Jose Leal
Ruth Coleman

Sponsor:University of Oxford

Funder:Diabetes Trials Unit, University of Oxford
Chief Scientist’s Office, Scotland

Reference number:IRAS: 249166

UKPDS was a randomised, multicentre trial of glucose-lowering and antihypertensive therapies in patients with newly diagnosed type 2 diabetes. The study showed that complications of diabetes could be reduced by more intensive blood glucose and/or blood pressure control using existing treatments and dramatically changed the management of type 2 diabetes worldwide.

The UKPDS Legacy Study is an extended follow-up of UKPDS using electronic health records and other routinely collected health data.


The UKPDS Legacy Study intends to obtain updated forty-year follow-up data for the original participants of the UKPDS study by accessing electronic health record data via NHS Digital and NHS Scotland.


To investigate whether early more intensive blood glucose and/or blood pressure control is associated with:

To assess the health economic impact of early more intensive blood glucose and/or blood pressure control over a lifetime horizon

Further Information

If you were a UKPDS participant, you can read the privacy notice for the UKPDS Legacy study here.


44-year UKPDS Legacy Effects Presented at the EASD

News Image

The 44-year UK Prospective Diabetes Study (UKPDS) follow-up results were presented today at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden. The new data from the UKPDS, one of the longest ever studies of diabetes, show that the problems experienced by people with type 2 diabetes, including heart attacks, kidney failure and vision loss are not inevitable, with the benefits of early good blood glucose control persisting for decades....

[Read more...]

[News archive]